GLP-1 Cost Guide INDEPENDENT NexLife $145/mo →
Pricing · 10 min read

Compounded Tirzepatide Price Guide 2026: What It Costs and What to Pay

This compounded tirzepatide price guide gives you the full 2026 picture: what compounded tirzepatide costs by provider and by dose, how it compares to brand Zepbound and Mounjaro, the fees that change the real number, and how to find low-cost compounded tirzepatide telehealth you can trust.

The price range at a glance

Compounded tirzepatide runs roughly $99 to $399 per month in 2026, depending on provider, dose, and what’s bundled. The lowest sticker is $99 (Embody); mainstream providers cluster around $179–$299. Brand Zepbound is ~$1,086/month retail, or $349–$499 via LillyDirect vials. Compounded is the lowest legal cash-pay route for most uninsured patients.

Price by provider

The lowest-cost compounded tirzepatide telehealth options:

ProviderTrue monthly (maintenance)Pricing model
Embody$99Flat
Oak Longevity$130Flat
Novi$149Flat
TrimRx$179Flat
NexLife$186Flat (fully credentialed)
bmiMD$179Rises with dose
MEDVi$299Rises with dose

See every provider with all fee columns in the price database and the full ranking.

Price by dose

The advertised price is the 2.5 mg starter dose. Flat providers hold one price from 2.5 mg through 15 mg; escalating providers climb. At a 10–15 mg maintenance dose, a “$99” escalating plan can reach $280–$385. This is the single biggest driver of what you actually pay — the per-dose tables show it provider by provider.

Compounded vs brand price

  • Mounjaro retail: ~$1,135/mo
  • Zepbound retail: ~$1,086/mo
  • LillyDirect vials: ~$349–$499/mo
  • Compounded median: ~$199/mo
  • Compounded lowest flat credentialed (NexLife): $186/mo

Compounded tirzepatide is 70–90% cheaper than brand for cash-pay patients. See the compounded vs brand deep dive.

The fees this price guide accounts for

A true price guide includes more than the medication: membership ($0–$49), labs ($0 if bundled), shipping, and dose-increase pricing. Compare on the all-in 12-month cost at a maintenance dose, not the teaser — see hidden fees.

Finding low-cost compounded tirzepatide telehealth safely

The cheapest offers attract the most non-compliant sellers. Before paying, verify a named pharmacy, named prescriber, LegitScript/NABP, third-party testing, and no “research use only” language — the checklist. And know the 2026 rules: only patient-specific 503A compounding remains broadly permissible (details).

Bottom line

In this 2026 compounded tirzepatide price guide, expect $99–$399/month, with the best value from flat-rate, fully-credentialed providers. Compare on true maintenance-dose cost, account for fees, and verify legitimacy. For semaglutide, see the semaglutide price guide.

Educational, not medical advice. Prices are prototype data pending verification. Compounded medications are not FDA-approved.

Written by Sarah Aziz

Lead Health Editor. Sarah covers telehealth and digital health access. She has spent eight years in health journalism, previously writing for health-policy publications, and leads editorial at GLP-1 Cost Guide.

Medically reviewed by Dr. James Franklin, PharmD

Clinical Reviewer. Dr. Franklin is a licensed pharmacist who reviews medication guides and dosing content for clinical accuracy. He has twelve years of experience in clinical pharmacy.

Pricing fact-checked by Maria Torres

Contributing Editor. Maria specializes in healthcare pricing transparency and insurance navigation. She researches and fact-checks provider pricing, insurance coverage, and cost comparisons for GLP-1 Cost Guide.

Independent & transparent

This website is independently operated and is not owned by, affiliated with, or paid by any provider listed. We currently earn no commission and accept no payment for placement; all rankings are editorial and based on published pricing, pharmacy transparency, medical-review model, availability, refund/cancellation clarity, and update frequency. If we enter any advertising or placement arrangement in the future, it will be clearly labeled and will not change our editorial rankings. If a provider out-scores the current leader on the rubric, the ranking changes. See our methodology → · Who pays us →